Minireviews
Copyright ©The Author(s) 2023.
World J Methodol. Jun 20, 2023; 13(3): 67-78
Published online Jun 20, 2023. doi: 10.5662/wjm.v13.i3.67
Figure 2
Figure 2 Clinical course after the appearance of hematuria. Hematuria and proteinuria persisted, and IgA nephropathy was suspected. Since there were some reports of IgA nephropathy caused by infliximab, we switched from infliximab to vedolizumab. After the change to vedolizumab, Crohn’s disease worsened, and there was a marked increase in proteinuria. Fever and abdominal symptoms worsened, and infliximab was administered again. Thereafter, Crohn’s disease improved rapidly, and decrease in the urinary protein level was noted. OB: Occult blood urine; U-TP/Cre: Urinary protein creatinine ratio; PCDAI: Pediatric Crohn’s disease activity index; y: years; m: Months.